Nct03504397 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nct03504397. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nct03504397 Today - Breaking & Trending Today

EMA Accepts Marketing Application for Zolbetuximab in CLDN18.2+ Gastric/GEJ Adenocarcinoma

The European Medicines Agency has accepted a marketing authorization application seeking the approval of zolbetuximab for first-line treatment of patients with Claudin18.2-positive, HER2-negative, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. ....

Moitreyee Chatterjee Kishore , Oncology Development At Astellas , European Medicines Agency , Immuno Oncology Development , Medicines Agency , Patients With Claudin18 2 Positive , Her2 Negative , Ocally Advanced Or Metastatic Gastric Gastroesophageal Junction Adenocarcinoma , Spotlight Trial , Glow Trial ,

Emerging Approaches for Gastric/GEJ Cancers Take the Spotlight at ASCO GI

Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium. ....

United States , New York , Memorial Sloan Kettering Cancer Center , Vanderbilt University , Kohei Shitara , Cathy Eng , Steve Maron , Davidh Johnson , American Society Of Clinical Oncology , European Society Of Medical Oncology , Tn Vanderbilt Ingram Cancer Center Codirector , Oncology At Vanderbilt University Medical Center , Vanderbilt Ingram Cancer Center , Clinical Oncology , Gastrointestinal Cancers Symposium , Targeted Therapies , Assistant Attending Physician , Steven Maron , Medical Oncology , Vanderbilt University Medical Center , European Society , Gi Cancers , Potlight Phase 3 Trial ,

CLDN18.2 Testing May Influence Advances in the Gastric Cancer Treatment Paradigm

Kevin M. Waters, MD, PhD, discusses key findings from a study that reinforced the rationale for Claudin18.2 testing, the prevalence of this protein in gastric cancers, and how this potential therapeutic target represents the evolving role of pathology in cancer diagnosis and care. ....

United States , Los Angeles , Laboratory Medicine At Cedars , Sinai Medical Center , Clinical Pathology Residency Program , Laboratory Medicine , Cedars Sinai Medical Center , Cedars Sinai , Claudin18 2 , Cldn18 2 , Spotlight Trial ,